Bioscience

Alzheimer’s discovery receives national attention

January 24, 2011

By Flinn Foundation

The endorsement by an FDA advisory panel of a new test to diagnose Alzheimer’s disease in living patients has ignited excitement among researchers and clinicians about potential benefits that Alzheimer’s patients may soon see.

The new test was developed by drugmaker Avid Radiopharmaceuticals, with important research contributions from scientists at the Phoenix-based Banner Alzheimer’s Institute. Eric Reiman, the institute’s executive director, and Pierre Tariot, director of the institute’s memory disorders center, were both interviewed by numerous Arizona and national media outlets, including: